EU Fast-Track Loss For GSK's Dostarlimab

 
• By Maureen Kenny

GSK’s potential endometrial cancer treatment dostarlimab is one of two products to revert to standard review timelines in recent weeks.

Timer
The EMA now wants more time to review the MAA for dostarlimab • Source: Shutterstock

More from Europe

More from Geography